Search Results - "Morales Murillo, S."

A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial by Gennari, A., Sun, Z., Hasler-Strub, U., Colleoni, M., Kennedy, M.J., Von Moos, R., Cortés, J., Vidal, M.J., Hennessy, B., Walshe, J., Parraga, K. Amillano, Ribi, K., Bernhard, J., Murillo, S. Morales, Pagani, O., Barbeaux, A., Borstnar, S., Rabaglio-Poretti, M., Maibach, R., Regan, M.M., Jerusalem, G.

“…The phase II SNAP trial was designed to evaluate the efficacy of alternative chemotherapy schedules for prolonged administration in HER2-negative metastatic…”
Get full text

Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study by Rugo, H.S., Oliveira, M., Howell, S.J., Dalenc, F., Cortes, J., Gomez, H.L., Hu, X., Jhaveri, K.L., Krivorotko, P., Loibl, S., Morales Murillo, S., Nowecki, Z., Okera, M., Park, Y.H., Sohn, J., Toi, M., Iwata, H., Yousef, S., Zhukova, L., Logan, J., Twomey, K., Khatun, M., D’Cruz, C.M., Turner, N.C.

“…Capivasertib is a potent, selective pan-AKT inhibitor. In CAPItello-291, the addition of capivasertib to fulvestrant resulted in a statistically significant (P…”
Get full text

P011 Utility of oncotype in premenopausal women with hormonal receptor (hr) positive her2 negative early breast cancer by Cudós, A. Gasol, Murillo, S. Morales, Der-Abrain, N. Tuset, Guzmán, D.R. Sánchez, Villellas, F. Vilardell, orillo, E. Morera M, Morales, C. Canosa, Olivé, J. Melé, Cid, L. Arbonés

Get full text

Pathologic response as a strong predictor of survival irrespective of phenotype in early breast cancer by Gasol Cudos, A., Morales Murillo, S., Veas Rodriguez, J., Vilardell Vilellas, F., Sanchez Guzman, D.R., Iglesias Martinez, E.

Get full text

Assesment of endocrine sensitivity in primary breast cancer through RS Score and changes in the proliferation index KI67 by Gasol Cudos, A., Morales Murillo, S., Pallisé Subirats, O., Rodriguez Galindo, A., Veas Rodriguez, J., Sanchez Guzman, D.R., Vilardell Villellas, F., Canosa Morales, C., Melé Olivé, J., Iglesias Martinez, E.

Get full text

Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers by Quintela-Fandino, M., Manso Sànchez, L.M., Holgado Martín, E., Moreno, M.C., Morales Murillo, S., Bermejo De Las Heras, B., Malon Gimenez, D., Colomer Bosch, R., Gonzalez Cortijo, L., Hornedo, J., Mouron, S., Muñoz, M., Escudero, S., Blanco, R., Mañes, S.

Get full text

4CPS-284 Treatment of cyclin inhibitor induced neutropenia: impact on progression free survival by Gilabert Sotoca, M, Morales Murillo, S, Mangues Bafalluy, I, Ramos Gil, MA, Morales Portillo, A, Rius Perera, J, Schoenenberger Arnaiz, JA

“…Background and importanceThe incidence of neutropenia in cyclin inhibitor (CI) treatment of luminal metastatic breast cancer (LMBC) is very high and leads to a…”
Get full text

Study of (p,2p) fission reactions in inverse kinematics using the R3B set-up by García-Jiménez, G., Alvarez-Pol, H., Graña-González, A., Rodríguez-Sánchez, J.L., Benlliure, J., Cortina-Gil, D., Atar, L., Audouin, L., Authelet, G., Besteiro, A., Blanchon, G., Boretzky, K., Borge, M.J.G., Cabanelas, P., Casarejos, E., Cederkall, J., Chatillon, A., Corsi, A., Feijoo, M., De Filippo, E., Galaviz, D., Gasparic, I., Geraci, E., Gernhäuser, R., Gnoffo, B., Heil, M., Heinz, A., Hensel, T., Holl, M., Jelavic Malenica, D., Jenegger, T., Ji, L., Johansson, H.T., Kiselev, O.A., Klenze, P., Knyazev, A., Körper, D., Kröll, T., Lithar, I., Litvinov, Y.A., Löher, B., Martorana, N. S., Morfouace, P., Mücher, D., Murillo-Morales, S., Obertelli, A., Panin, V., Park, J., Paschalis, S., Perea, A., Petri, M., Pirrone, S., Ponnath, L., Revel, A., Rhee, H., Rose, L., Rossi, D.M., Russotto, P., Simon, H., Stott, A., Sun, Y., Sürder, C., Taïeb, J., Taniuchi, R., Tengblad, O., Törnqvist, H.T., Trimarchi, M., Velardita, S., Vesic, J., Voss, B.

“…A new experimental fission approach is presented in the context of the R 3 B (Reactions with Relativistic Radioactive Beams) collaboration, at the GSI/FAIR…”
Get full text

1944 Pathological complete response (pCR) after neoadjuvant chemotherapy in luminal breast cancer by Córdoba Ortega, J.F, Gasol Cudós, A, Morales Murillo, S, Vilardell Villellas, F, Sisó Raber, C, Canosa Morales, C, Salud Salvia, A

Get full text

Change in treatment decisions according to Oncotype Dx Recurrence Score in node positive and negative, estrogen-receptor positive (ER+), HER2 negative breast cancer in a single institution by Gasol Cudos, A, Morales Murillo, S, Panades Siurana, M.J, Vilardell Villellas, F, Canosa Morales, C, Mele Olive, J, Iglesias Martinez, E, Salud Salvia, A

Get full text

372P The prognostic value of liver metastases and how affects the applicability of the lung-molGPA in non-small cell lung cancer patients with brain metastases by Veas Rodriguez, J.R., Morales Murillo, S., Rodriguez Galindo, A., Pallisé Subirats, O., Cordoba Ortega, J.F.

Get full text

Comprehensive investigation of fission yields by using spallation- and (p,2p)-induced fission reactions in inverse kinematics by Rodríguez-Sánchez, J. L, Graña-González, A, Benlliure, J, Chatillon, A, García-Jiménez, G, Taieb, J, Alvarez-Pol, H, Atar, L, Audouin, L, Authelet, G, Besteiro, A, Blanchon, G, Boretzky, K, Cabanelas, P, Casarejos, E, Cederkall, J, Cortina-Gil, D, Corsi, A, De Filippo, E, Feijoo, M, Galaviz, D, Gasparic, I, Gernhäuser, R, Haettner, E, Heil, M, Heinz, A, Holl, M, Jenegger, T, Ji, L, Johansson, H. T, Kelić-Heil, A, Kiselev, O. A, Klenze, P, Knyazev, A, Körper, D, Kröll, T, Lihtar, I, Litvinov, Y. A, Löher, B, Martorana, N, Morfouace, P, Mücher, D, Morales, S. Murillo, Obertelli, A, Panin, V, Park, J, Paschalis, S, Perea, A, Petri1, M, Pietri, S, Pirrone, S, Ponnath, L, Revel, A, Rhee, H. -B, Rose, L, Ross, D. M, Russotto, P, Simon, H, Stott, A, Sun, Y, Sürder, C, Taniuchi, R, Tengblad, O, Törnqvist, H. T, Trimarchi, M, Velardita, S, Vesic, J, Voss, B, Weick, H

“…In the last decades, measurements of spallation, fragmentation and Coulex induced fission reactions in inverse kinematics have provided valuable data to…”
Get full text

180P Relapse pattern after neoadjuvant treatment in early breast cancer by Gasol Cudos, A., Morales Murillo, S., Pallisé Subirats, O., Vilardell Villellas, F., Sánchez Guzman, D.R., Canosa Morales, C., Melé Olivé, J., Velasco Sánchez, A., Cordoba Ortega, J.F.

Get full text

Abstract P2-08-30: Vitamin D as a prognostic factor in triple negative early breast cancer by Morales Murillo, S, Gasol Cudos, A, Veas Rodriguez, J, Santacana, M, Canosa Morales, C, Mele Olivé, J

“…Abstract Background: Triple negative breast cancer is a special phenotype where the pathological complete response (pCR) remains the most important factor but…”
Get full text

264PPathologic response as a strong predictor of survival irrespective of phenotype in early breast cancer by Gasol Cudos, A, Morales Murillo, S, Veas Rodriguez, J, Vilardell Vilellas, F, Sanchez Guzman, D R, Iglesias Martinez, E

Get full text

40TiP SOLTI-1802 ONAWA trial: A window of opportunity trial of onapristone (ONA) in postmenopausal women with estrogen and progesterone receptor-positive/HER2-negative (ER+/PgR+/HER2-) early breast cancer (EBC) by Bellet, M., Morales Murillo, S., Gasol Cudos, A., Amillano, K., Chic, N., González-Farré, X., Villagrasa, P., Ferrero-Cafiero, J.M., Pascual, T., Prat, A., Lange, C., Saura Manich, C.

Get full text

266PPathologic response and survival efficacy in patients with initial nodal involvement after neoadjuvant chemotherapy in early breast cancer by Murillo, S Morales, Cudos, A Gasol, Rodriguez, J Veas, Villellas, F Vilardell, Guzmán, D -R Sánchez, Morales, C Canosa, Olivé, J Melé, el Koulali, I, Martínez, E Iglesias

“…Abstract Background Nodal involvement is a common prognostic factor in early breast cancer (EBC) but their response and assessment after neoadjuvant…”
Get full text

266P - Pathologic response and survival efficacy in patients with initial nodal involvement after neoadjuvant chemotherapy in early breast cancer by Murillo, S Morales, Cudos, A Gasol, Rodriguez, J Veas, Villellas, F Vilardell, Guzmán, D -R Sánchez, Morales, C Canosa, Olivé, J Melé, el Koulali, I., Martínez, E Iglesias

“…Nodal involvement is a common prognostic factor in early breast cancer (EBC) but their response and assessment after neoadjuvant chemotherapy (NAC) is…”
Get full text

Pathologic response and survival efficacy in patients with initial nodal involvement after neoadjuvant chemotherapy in early breast cancer by Murillo, S Morales, Cudos, A Gasol, Rodriguez, J Veas, Villellas, F Vilardell, Guzmán, D -R Sánchez, Morales, C Canosa, Olivé, J Melé, el Koulali, I., Martínez, E Iglesias

Get full text

205TiP ATRACTIB: A phase II trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC) by Cortés Salgado, A., Perez Garcia, J.M., Cortez Castedo, S.P., Gion Cortes, M., Morales Murillo, S., Blancas López-Barajas, I., Blanch, S., Calvo Plaza, I., Diaz Fernandez, N., Marmé, F., Martinez Bueno, A., Taberner Bonastre, M.T., De Laurentiis, M., Ruiz Borrego, M., Schmid, P., Guarneri, V., Gligorov, J., Sampayo-Cordero, M., Llombart Cussac, A., Cortés, J.

Get full text